Scientists restored young gut bacteria in aging mice and saw signs of rejuvenation along with complete protection from liver cancer.
Category: biotech/medical – Page 79
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
Current therapies offer limited benefit for patients with previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC). Aberrant activation of the RAS pathway is the key driver of PDAC, with oncogenic RAS mutations present in more than 90% of cases. Daraxonrasib is an oral RAS(ON) multiselective, tri-complex inhibitor of the active guanosine triphosphate–bound state of mutant and wild-type RAS.
Longevity Scientist: Aging Will Soon Be Treatable But Immortality Is Not the Goal
Can we really slow aging or even reverse it?
Aging is no longer viewed as an untouchable part of life. According to Eric Verdin, scientists are beginning to treat aging itself as a biological process that can be slowed and potentially reversed.
In this episode, Eric explains why longevity research is entering a new era. He discusses how AI, women’s health, metabolic therapies, and partial reprogramming are reshaping medicine. He highlights GLP-1 drugs as one of the most promising tools today and explains how resetting cells to a younger state may one day restore function in aging tissues.
He also shares the most effective strategies available right now: exercise, sleep, nutrition, mental stimulation, and social connection. While supplements like Creatine may help, Eric stresses that lifestyle remains the foundation of long-term health.
Eric Verdin is a physician-scientist and CEO of the Buck Institute for Research on Aging, where he leads research focused on extending human healthspan.
What You’ll Learn.
Chris Hables Gray on AI and the Singularity: We Need Strong Citizenship!
In 2013, I interviewed a man who studies cyborgs and war for a living.
Somewhere in that conversation, Prof. Chris Hables Gray predicted a global pandemic. I chimed in that it would most likely stem from a bird flu outbreak.
We were both right. Neither of us wanted to be.
That was six years before COVID. And here we are in 2026, watching H5N1 headlines pile up again.
The point was never the prediction. The point was what he said we should do about it.
Chris did not pitch a gadget. He did not sell a forecast. He argued that surviving the century is not a technology problem; it is a citizenship problem.
How swarms of tiny light-controlled robots could revolutionize wound care
Having a swarm of microbots moving across your body may sound like the stuff of a horror movie, but it could actually be the future of targeted drug delivery and advanced wound healing. Scientists have developed a way to use blue and red light as a remote control to assemble and disperse swarms of biohybrid microrobots that could one day transform how we treat injuries.
Details of the research are in a paper published in the journal Science Advances.
The microrobots come in two parts. The first is a living green microalga called Chlamydomonas reinhardtii (CR), which uses two tail-like structures (flagella) to swim through aquatic environments and respond to light.
Toward cheaper, cleaner hydrogen production
Sobek was born and raised in Argentina, but he also grew up at MIT over the course of three degrees and more than a decade. He first studied aeronautics and astronautics at MIT, then jumped to mechanical engineering as a graduate student, then moved to the Department of Electrical Engineering and Computer Science, where he worked under PhD advisors and MIT professors Martha Gray and Stephen Senturia. His thesis focused on a technique for quickly measuring optical properties of large numbers of biological cells.
“A lot of my learnings around microfabrication and materials chemistry ended up being really relevant for 1s1,” Sobek says. “A class that was very important to me was taught by Professor Amar Bose. I was a teaching assistant for him for a couple of semesters, and that had an incredible influence on my thinking.”
Following graduation, Sobek worked in microelectronics and microfluidics before founding his own company, Zymera, in 2004. The company developed deep-tissue imaging technology for detecting cancer and other serious diseases.
Harvard Publishes a Longevity Report for the General Public
The report, titled “Pathways to Longevity”, introduces several important longevity concepts to the general reader and is another sign that the field is coming of age and entering the mainstream.
People do want to live longer
From time to time, Harvard Health Publishing issues Special Health Reports – consumer-facing, doctor-reviewed guides translating medical research for general readers. Previous reports included topics such as Alzheimer’s and heart disease. This new one, presented to the public earlier this week, is dedicated to healthy longevity. While this report, aimed mostly at curious laypeople and priced at $29, might not reveal a trove of new information to a longevity-savvy reader, it is an unmistakable sign that longevity science and the very idea of extending lifespan and healthspan are finally entering the mainstream.
Researchers block key protein that helps Parkinson’s spread through the brain
A newly identified protein called GPNMB may play a major role in helping Parkinson’s disease spread through the brain. Researchers discovered that immune cells release the protein in response to damaged neurons, creating a vicious cycle that speeds up brain cell degeneration. In early experiments, antibodies that blocked GPNMB stopped the toxic process from spreading between cells.